首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1780305

疫苗市場規模及預測 2021-2031、全球及地區佔有率、趨勢及成長機會分析報告涵蓋：類型、適應症、給藥途徑、年齡層及地理

Vaccines Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type, Indication, Route of Administration, Age Group, and Geography

出版日期: 2025年07月07日 | 出版商:

The Insight Partners | 英文 226 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

疫苗市場規模預計將從2024年的804.5億美元成長到2031年的1,189.4億美元；預計2025-2031年期間的複合年成長率為5.7%。傳染病和疾病爆發的發生率不斷上升，以及免疫接種計畫和政府措施的不斷湧現，都是推動疫苗市場規模擴張的重要因素。然而，疫苗開發成本高昂以及上市時間過長阻礙了疫苗市場的成長。

人工智慧 (AI) 和機器學習正在透過引入提高速度和準確性的創新方法，重塑疫苗研發的格局。人工智慧最關鍵的應用之一是分析複雜的基因組和免疫學資料。這項技術使研究人員能夠透過篩選大量數據來快速識別潛在的疫苗標靶——這一過程傳統上需要數年才能完成。預測針對這些標靶的免疫反應的能力尤其具有革命性，為在更短的時間內設計疫苗提供了寶貴的見解。

在新冠疫情期間，人工智慧的戰略價值顯而易見。它在加速mRNA疫苗研發臨床試驗進度方面發揮了關鍵作用，使企業能夠在一年內完成從病毒基因組測序到獲得監管部門批准的整個流程。 2021年，輝瑞利用先進的人工智慧驅動平台SDQ簡化了臨床資料處理。這款機器學習工具將清理和分析試驗資料所需的時間從達到療效里程碑後的30多天縮短至僅需22小時，顯著提高了營運效率和上市速度。

在製造業領域，人工智慧的實施顯著提高了生產效率。人工智慧系統可以簡化生產流程的各個階段，透過監控和識別與預期標準的偏差來加強品質控制，並預測可能延遲疫苗交付的潛在瓶頸。這種積極主動的方法不僅加快了生產進度，還能確保疫苗生產具有更高的可靠性。 2025年3月，洛斯阿拉莫斯宣布，洛斯阿拉莫斯國家實驗室的科學家正在將實驗資料與人工智慧結合，以加速疫苗和藥物的開發。 RAPTER疫苗開發計畫正在利用人工智慧和實驗研究來加速傳統的研究方法。該計畫旨在創建一種預測工具，用於分析病原體基因序列並識別有效的疫苗方案，以快速應對疫情。該團隊正在開發該工具，使用基於人工智慧的知識提取、機制建模以及體外和體內實驗來測試有前景的候選疫苗。最初，RAPTER 將重點放在三種病原體：SARS-CoV-2、伊波拉病毒和伯克霍爾德菌（一種導致類鼻疽的細菌），被認為是一種重大生物威脅。

整體而言，將人工智慧和機器學習融入疫苗開發流程，將使這一關鍵領域更加高效、更具可擴展性，並更能適應全球健康威脅的快速變化，最終有助於更有效的公共衛生應對。預計這將有助於未來幾年疫苗市場的成長。

基於年齡的洞察

根據年齡段，疫苗市場分為兒童和成人兩類。 2024年，兒童疫苗佔據了最大的市場。兒童疫苗是在嬰兒期和兒童時期接種的疫苗，用於預防在生命早期構成重大風險的傳染病。這些疫苗通常被納入國家免疫計劃，涵蓋的免疫接種範圍包括白喉、百日咳、破傷風 (DTP)、脊髓灰質炎、輪狀病毒、麻疹、腮腺炎、德國麻疹 (MMR)、B肝、肺炎球菌等疾病。由於人們對兒童早期免疫意識的不斷提高、各組織加強全球覆蓋力度以及已開發國家和發展中國家政府的強力要求，兒童疫苗市場持續成長。嬰兒疫苗可預防疾病的負擔以及早期免疫帶來的長期健康和經濟效益，促使相關部門持續提供政策和資金支持。減少注射次數的聯合疫苗（例如五價或六價疫苗）以及兒童HPV疫苗和瘧疾疫苗等新增疫苗進一步擴大了兒科疫苗的種類。疫苗技術的進步，例如耐熱和無針給藥系統，也支持了資源匱乏地區的疫苗普及，推動了疫苗市場的成長。

世界衛生組織和聯合國兒童基金會是撰寫疫苗市場報告時參考的主要和次要來源之一。

疫苗市場－關鍵市場動態
市場促進因素
- 傳染病和疾病爆發的發生率不斷上升
- 免疫接種計畫和政府措施激增
市場限制
- 疫苗研發成本高，上市時間延長
市場機會
- 聯合疫苗和治療性疫苗的開發
未來趨勢
- 人工智慧與巨量資料在疫苗研發中的融合
促進因素和限制因素的影響：

第6章：疫苗市場－全球市場分析

疫苗 - 全球市場概覽
疫苗－全球市場及2031年預測

第7章：疫苗市場-收入分析-按技術，2020-2031

概述
減毒活疫苗
去活化疫苗和次單位疫苗
類毒素疫苗
結合疫苗
重組疫苗
其他

第 8 章：疫苗市場 - 收入分析 - 按疾病適應症，2020-2031 年

概述
流感
登革熱
鉅細胞病毒（CMV）
肝炎
呼吸道合胞病毒（RSV）
其他疾病

第9章：疫苗市場-收入分析-依給藥途徑，2020-2031

概述
口服
注射劑
其他給藥途徑

第 10 章：疫苗市場 - 收入分析 - 依病患類型，2020-2031 年

概述
兒科
成人

第 11 章：疫苗市場 - 收入分析，2020-2031 - 地理分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 亞太地區其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 12 章：產業格局

合併與收購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 13 章：競爭格局

關鍵參與者的熱圖分析
按關鍵參與者排名

第 14 章：疫苗市場 - 主要公司簡介

GlaxoSmithKline plc
Pfizer Inc.
Sanofi
Merck and Co., Inc
Serum Institute of India (SII)
BioNTech
Abbott
Sinovac
Novartis
CSL Seqirus

第 15 章：附錄

簡介目錄圖表

Product Code: TIPRE00015468

The vaccines market size is expected to grow from US$ 80.45 billion in 2024 to US$ 118.94 billion by 2031; it is projected to register a CAGR of 5.7% during 2025-2031. The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives are noteworthy factors contributing to the expansion of the vaccines market size. However, the high vaccine development cost and increased time to market hinder the vaccines market growth.

Artificial intelligence (AI) and machine learning are reshaping the landscape of vaccine research and development by introducing innovative methodologies that enhance speed and accuracy. One of the most critical applications of AI is in the analysis of complex genomic and immunological data. This technology enables researchers to rapidly identify potential vaccine targets by sifting through vast amounts of data-a process that would have traditionally taken years to accomplish. The ability to predict immune responses to these targets is particularly revolutionary, providing insights to design vaccines in a much shorter timeframe.

The strategic value of AI was evident during the COVID-19 pandemic, where it played a critical role in accelerating mRNA vaccine development clinical trials timelines, enabling companies to move from viral genome sequencing to regulatory approval within a year. In 2021, Pfizer leveraged an advanced AI-driven platform, SDQ, to streamline clinical data processing. This machine learning tool reduced the time required to clean and analyze trial data from over 30 days to just 22 hours after reaching efficacy milestones, significantly enhancing operational efficiency and speed to market.

In the manufacturing arena, the implementation of AI significantly enhances production efficiency. AI systems can streamline various stages of the production process, enhance quality control by monitoring and identifying deviations from expected standards, and forecast potential bottlenecks that could delay vaccine delivery. This proactive approach not only speeds up the production timeline but also ensures that vaccines are manufactured with a higher degree of reliability. In March 2025, Los Alamos announced that the scientists in Los Alamos National Laboratory are combining experimental data and AI for accelerating vaccine and drug development. The RAPTER vaccine development project is leveraging AI and experimental studies to expedite traditional research methods. It aims to create a predictive tool that analyzes pathogen genetic sequences and identifies effective vaccine options for rapid outbreak responses. The team is developing this tool using AI-based knowledge extraction, mechanistic modeling, and in vitro and in vivo experiments to test promising candidates. Initially, RAPTER will focus on three pathogens: SARS-CoV-2, Ebola virus, and Burkholderia pseudomallei, the bacterium that causes melioidosis, deemed a significant biological threat.

Overall, the integration of AI and machine learning into vaccine development processes is making this critical field more efficient, scalable, and adaptable to the rapidly evolving landscape of global health threats, ultimately contributing to more effective public health responses. This is expected to contribute to the growth of the vaccines market in the coming years.

Age Group -Based Insights

Based on age group, the vaccines market is segmented into pediatric and adult. The pediatric segment held the largest vaccines market share in 2024. Pediatric vaccines are immunizations given during infancy and childhood to protect against infectious diseases that pose significant risks in early life. These vaccines are typically scheduled in national immunization programs and include protection against diseases such as diphtheria, pertussis, tetanus (DTP), polio, rotavirus, measles, mumps, rubella (MMR), hepatitis B, pneumococcal, and more. This segment continues to grow due to rising awareness about early childhood immunity, increased global coverage efforts by organizations, and strong government mandates in both developed and developing countries. The burden of vaccine-preventable diseases in infants and the long-term health and economic benefits of early immunization have led to sustained policy and funding support. Combination vaccines that reduce the number of injections (e.g., pentavalent or hexavalent) and newer additions like HPV and malaria vaccines for children have further expanded the pediatric portfolio. Advances in vaccine technology, such as thermostable and needle-free delivery systems, also support outreach in low-resource areas, thereby fueling the vaccines market growth.

The World Health Organization and UNICEF are among the primary and secondary sources referred to while preparing the vaccines market report.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Vaccines Market - Key Market Dynamics

5.1 Vaccines Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
- 5.2.2 Surging Immunization Programs and Government Initiatives
5.3 Market Restraints
- 5.3.1 High Vaccine Development Cost and Increased Time to Market
5.4 Market Opportunities
- 5.4.1 Development of Combination and Therapeutic Vaccines
5.5 Future Trends
- 5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development
5.6 Impact of Drivers and Restraints:

6. Vaccines Market - Global Market Analysis

6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2031

7. Vaccines Market - Revenue Analysis (USD Million) - By Technology, 2020-2031

7.1 Overview
7.2 Live Attenuated Vaccines
- 7.1.1 Overview
- 7.1.2 Live Attenuated Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Inactivated Vaccines and Subunit Vaccines
- 7.2.1 Overview
- 7.2.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Toxoid Vaccines
- 7.3.1 Overview
- 7.3.2 Toxoid Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Conjugate Vaccines
- 7.3.1 Overview
- 7.3.2 Conjugate Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Recombinant Vaccines
- 7.3.1 Overview
- 7.3.2 Recombinant Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Others

8. Vaccines Market - Revenue Analysis (USD Million) - By Disease Indication, 2020-2031

8.1 Overview
8.2 Influenza
- 8.1.1 Overview
- 8.1.2 Influenza: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Dengue
- 8.1.1 Overview
- 8.1.2 Dengue: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Cytomegalovirus (CMV)
- 8.1.1 Overview
- 8.1.2 Cytomegalovirus (CMV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Hepatitis
- 8.1.1 Overview
- 8.1.2 Hepatitis: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Respiratory Synical Virus (RSV)
- 8.1.1 Overview
- 8.1.2 Respiratory Synical Virus (RSV): Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Other Diseases
- 8.1.1 Overview
- 8.1.2 Other Diseases: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

9. Vaccines Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2031

9.1 Overview
9.2 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Injectable
- 9.1.1 Overview
- 9.1.2 Injectable: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Other Route of Administration
- 9.1.1 Overview
- 9.1.2 Other Route of Administration: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

10. Vaccines Market - Revenue Analysis (USD Million) - By Patient Type, 2020-2031

10.1 Overview
10.2 Pediatric
- 10.2.1 Overview
- 10.2.2 Pediatric: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Adult
- 10.3.1 Overview
- 10.3.2 Adult: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)

11. Vaccines Market - Revenue Analysis (USD Million), 2020-2031 - Geographical Analysis

11.1 North America
- 11.1.1 North America Vaccines Market Overview
- 11.1.2 North America Vaccines Market Revenue and Forecasts to 2031
- 11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
- 11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication
- 11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
- 11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type
- 11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
  - 11.1.7.1 United States Vaccines Market
    - 11.1.7.1.1 United States Vaccines Market, by Technology
    - 11.1.7.1.2 United States Vaccines Market, by Disease Indication
    - 11.1.7.1.3 United States Vaccines Market, by Route of Administration
    - 11.1.7.1.4 United States Vaccines Market, by Patient Type
  - 11.1.7.2 Canada Vaccines Market
    - 11.1.7.2.1 Canada Vaccines Market, by Technology
    - 11.1.7.2.2 Canada Vaccines Market, by Disease Indication
    - 11.1.7.2.3 Canada Vaccines Market, by Route of Administration
    - 11.1.7.2.4 Canada Vaccines Market, by Patient Type
  - 11.1.7.3 Mexico Vaccines Market
    - 11.1.7.3.1 Mexico Vaccines Market, by Technology
    - 11.1.7.3.2 Mexico Vaccines Market, by Disease Indication
    - 11.1.7.3.3 Mexico Vaccines Market, by Route of Administration
    - 11.1.7.3.4 Mexico Vaccines Market, by Patient Type
11.2 Europe
- 10.2.1 Europe Vaccines Market Overview
- 10.2.2 Europe: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.2.2.1 Europe: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.2.2.2 Europe: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.2.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.2.2.4 Europe: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.2.2.5 Europe: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.2.2.6 Europe: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.2.3 Europe: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 Germany: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
    - 10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
    - 10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.2 United Kingdom: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
    - 10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
    - 10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.3 France: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
    - 10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza
    - 10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.4 Italy: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology
    - 10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza
    - 10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.5 Spain: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology
    - 10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza
    - 10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration
  - 10.2.3.6 Rest of Europe: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology
    - 10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication
    - 10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza
    - 10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration
10.3 Asia Pacific
- 10.3.1 Asia Pacific Vaccines Market Overview
- 10.3.2 Asia Pacific: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.3.2.1 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.3.2.2 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.3.2.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.3.2.4 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.3.2.5 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.3.2.6 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.3.3 Asia Pacific: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 China: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.1.1 China: Vaccines Market Breakdown, by Technology
    - 10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza
    - 10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.2 India: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.2.1 India: Vaccines Market Breakdown, by Technology
    - 10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza
    - 10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.3 Japan: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology
    - 10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza
    - 10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.4 Australia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology
    - 10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza
    - 10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.5 South Korea: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology
    - 10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza
    - 10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration
  - 10.3.3.6 Rest of APAC: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology
    - 10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication
    - 10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza
    - 10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration
10.4 Middle East and Africa
- 10.4.1 Middle East and Africa Vaccines Market Overview
- 10.4.2 Middle East and Africa: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.4.2.1 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.4.2.2 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.4.2.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.4.2.4 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.4.2.5 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.4.2.6 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.4.3 Middle East and Africa: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 South Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.2 Saudi Arabia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology
    - 10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza
    - 10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.3 United Arab Emirates: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology
    - 10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza
    - 10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration
  - 10.4.3.4 Rest of Middle East and Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology
    - 10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication
    - 10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza
    - 10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration
10.5 South and Central America
- 10.5.1 South and Central America Vaccines Market Overview
- 10.5.2 South and Central America: Vaccines Market - Revenue, 2021-2031 (US$ Million)
  - 10.5.2.1 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Technology
  - 10.5.2.2 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Live Attenuated Vaccines
  - 10.5.2.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Inactivated Vaccines and Subunit Vaccines
  - 10.5.2.4 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Disease Indication
  - 10.5.2.5 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Influenza
  - 10.5.2.6 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Route of Administration
- 10.5.3 South and Central America: Vaccines Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Brazil: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology
    - 10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza
    - 10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.2 Argentina: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology
    - 10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza
    - 10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration
  - 10.5.3.3 Rest of South and Central America: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology
    - 10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines
    - 10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
    - 10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication
    - 10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza
    - 10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration

12. Industry Landscape

12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

13.1 Heat Map Analysis by Key Players
13.2 Ranking by Key Players

14. Vaccines Market - Key Company Profiles

14.1 GlaxoSmithKline plc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Merck and Co., Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Serum Institute of India (SII)
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 BioNTech
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Abbott
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Sinovac
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Novartis
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 CSL Seqirus
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud

簡介目錄圖表

List Of Tables

Table 1. Vaccines Market Segmentation
Table 2. Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 3. Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 4. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 5. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 6. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 7. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 8. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 9. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 10. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 11. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 12. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 13. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 14. North America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 15. North America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 16. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 17. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 18. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 19. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 20. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 21. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 22. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 23. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 24. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 25. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 26. United States: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 27. United States: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 28. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 29. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 30. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 31. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 32. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 33. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 34. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 35. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 36. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 37. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 38. Canada: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 39. Canada: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 40. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 41. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 42. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 43. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 44. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 45. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 46. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 47. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 48. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 49. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 50. Mexico: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 51. Mexico: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 52. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 53. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 54. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 55. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 56. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 57. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 58. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 59. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 60. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 61. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 62. Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 63. Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 64. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 65. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 66. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 67. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 68. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 69. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 70. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 71. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 72. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 73. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 74. Germany: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 75. Germany: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 76. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 77. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 78. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 79. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 80. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 81. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 82. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 83. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 84. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 85. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 86. United Kingdom: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 87. United Kingdom: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 88. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 89. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 90. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 91. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 92. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 93. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 94. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 95. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 96. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 97. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 98. France: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 99. France: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 100. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 101. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 102. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 103. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 104. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 105. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 106. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 107. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 108. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 109. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 110. Italy: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 111. Italy: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 112. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 113. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 114. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 115. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 116. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 117. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 118. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 119. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 120. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 121. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 122. Spain: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 123. Spain: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 124. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 125. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 126. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 127. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 128. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 129. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 130. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 131. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 132. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 133. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 134. Rest of Europe: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 135. Rest of Europe: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 136. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 137. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 138. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 139. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 140. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 141. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 142. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 143. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 144. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 145. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 146. Asia Pacific: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 147. Asia Pacific: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 148. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 149. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 150. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 151. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 152. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 153. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 154. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 155. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 156. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 157. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 158. China: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 159. China: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 160. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 161. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 162. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 163. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 164. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 165. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 166. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 167. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 168. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 169. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 170. India: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 171. India: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 172. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 173. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 174. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 175. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 176. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 177. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 178. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 179. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 180. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 181. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 182. Japan: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 183. Japan: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 184. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 185. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 186. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 187. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 188. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 189. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 190. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 191. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 192. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 193. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 194. Australia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 195. Australia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 196. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 197. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 198. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 199. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 200. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 201. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 202. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 203. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 204. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 205. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 206. South Korea: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 207. South Korea: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 208. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 209. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 210. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 211. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 212. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 213. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 214. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 215. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 216. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 217. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 218. Rest of APAC: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 219. Rest of APAC: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 220. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 221. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 222. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 223. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 224. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 225. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 226. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 227. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 228. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 229. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 230. Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 231. Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 232. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 233. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 234. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 235. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 236. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 237. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 238. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 239. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 240. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 241. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 242. South Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 243. South Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 244. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 245. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 246. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 247. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 248. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 249. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 250. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 251. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 252. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 253. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 254. Saudi Arabia: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 255. Saudi Arabia: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 256. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 257. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 258. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 259. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 260. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 261. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 262. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 263. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 264. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 265. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 266. United Arab Emirates: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 267. United Arab Emirates: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 268. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 269. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 270. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 271. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 272. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 273. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 274. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 275. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 276. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 277. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 278. Rest of Middle East and Africa: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 279. Rest of Middle East and Africa: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 280. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 281. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 282. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 283. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 284. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 285. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 286. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 287. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 288. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 289. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 290. South and Central America: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 291. South and Central America: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 292. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 293. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 294. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 295. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 296. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 297. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 298. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Disease Indication
Table 299. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Disease Indication
Table 300. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Influenza
Table 301. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Influenza
Table 302. Brazil: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Route of Administration
Table 303. Brazil: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Route of Administration
Table 304. Argentina: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Technology
Table 305. Argentina: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Technology
Table 306. Argentina: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Live Attenuated Vaccines
Table 307. Argentina: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Live Attenuated Vaccines
Table 308. Argentina: Vaccines Market - Revenue, 2021-2024 (US$ Million) - by Inactivated Vaccines and Subunit Vaccines
Table 309. Argentina: Vaccines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Inactivated

List Of Figures

Figure 1. Vaccines Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Vaccines Market Revenue (US$ Million), 2021-2031
Figure 5. Vaccines Market Revenue (US$ Million), 2021-2031
Figure 6. Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 7. Live Attenuated Vaccines: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Livestock and Poultry: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines Market Share (%) - by Disease Indication (2024 and 2031)
Figure 10. Influenza: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Medical Devices: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Feed Additives: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Vaccines Market Share (%) - by Route of Administration (2024 and 2031)
Figure 14. Veterinary Hospitals: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Clinics: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Others: Vaccines Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. North America: Vaccines Market - Revenue, 2021-2031 (US$ Million)
Figure 18. North America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 19. United States: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 20. Canada: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 21. Mexico: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 22. Europe: Vaccines Market - Revenue, 2021-2031 (US$ Million)
Figure 23. Europe: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 24. Germany: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 25. United Kingdom: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 26. France: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 27. Italy: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 28. Spain: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 29. Rest of Europe: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 30. Asia Pacific: Vaccines Market - Revenue, 2021-2031 (US$ Million)
Figure 31. Asia Pacific: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 32. China: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 33. India: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 34. Japan: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 35. Australia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 36. South Korea: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 37. Rest of APAC: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 38. Middle East and Africa: Vaccines Market - Revenue, 2021-2031 (US$ Million)
Figure 39. Middle East and Africa: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 40. South Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 41. Saudi Arabia: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 42. United Arab Emirates: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 43. Rest of Middle East and Africa: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 44. South and Central America: Vaccines Market - Revenue, 2021-2031 (US$ Million)
Figure 45. South and Central America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 46. Brazil: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 47. Argentina: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 48. Rest of South and Central America: Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Million)